Abstract: A device for checking K phase current sensors for capturing measured values of K corresponding phase currents of an N-phase, electrical load, in particular an electrical machine, with N?3 and with K<N, is provided. The device is configured to cause the N-phase load to be operated for a test period in a test operating mode in which the sum of the K phase currents, which are captured by the K corresponding phase current sensors, corresponds to a predefined value, in particular zero. Furthermore, the device is configured to determine K measured values from the K corresponding phase current sensors during the test period, and to check at least one of the K phase current sensors on the basis of the K measured values.

Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III or a pharmaceutically acceptable salt thereof.

Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III or a pharmaceutically acceptable salt thereof.

Abstract: A device (2) for demagnetizing and for measuring the magnetic signature of a stationary hull (4) and for simulating a magnetic field, including a demagnetization coil assembly (8), a magnetic field sensor assembly (10) and a simulation coil assembly (12a, 12b, 12c), which can be positioned next to the hull (4) in a horizontal manner on one side and the cross-sectional areas of the demagnetization coils (8) and of the simulation coils (12a, 12b, 12c) being disposed in the longitudinal direction of the hull (4) with horizontally oriented surface normals. The demagnetization coils (8) produce an alternating magnetic field; the simulation coils (12a, 12b, 12c) produce a stationary simulated magnetic field in all three dimensions.

Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III or a pharmaceutically acceptable salt thereof.

Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitor of formula III or a pharmaceutically acceptable salt thereof.

Abstract: This invention concerns a process for producing particle foam part in which foam particles are heated in a molding tool so that they weld to the particle foam part. Heat is supplied to the foam particles by means of electromagnetic RF radiation. The foam particles are made of polyurethane (PU), polylactate (PLA), polyethylene block amide (PEBA) or polyethylene terephthalate (PET).

Abstract: A device (2) for demagnetizing and for measuring the magnetic signature of a stationary hull (4) and for simulating a magnetic field, including a demagnetization coil assembly (8), a magnetic field sensor assembly (10) and a simulation coil assembly (12a, 12b, 12c), which can be positioned next to the hull (4) in a horizontal manner on one side and the cross-sectional areas of the demagnetization coils (8) and of the simulation coils (12a, 12b, 12c) being disposed in the longitudinal direction of the hull (4) with horizontally oriented surface normals. The demagnetization coils (8) produce an alternating magnetic field; the simulation coils (12a, 12b, 12c) produce a stationary simulated magnetic field in all three dimensions.

Abstract: A coil system (30, 40, 50) for generating a homogeneous magnetic field, includes a coil assembly (2), each assembly having at least two coils (S1, S2, S3), the respective windings (W1, W-2, W3) of which span. rotationally symmetrical faces lying plane-parallel to one another having different sizes and a common axis of rotation running perpendicularly to the faces, forming a coil axis (4), wherein a current can flow in the opposite direction through at least one of the coils (S1, S2, S3), and having at least two coil assemblies (2), wherein the coils (S1, S2, S3) of each coil assembly (2) are located within and oriented plane-parallel to the base of a generating pyramid, the tip of which coincides with the centre of a regular convex polyhedron and the base surface of which is identical to one such face of the convex polyhedron, on which the projection of the pyramid tip onto the pyramid base surface coincides with the centre of the pyramid base surface.

Abstract: This invention concerns a process for producing particle foam part in which foam particles are heated in a molding tool so that they weld to the particle foam part. Heat is supplied to the foam particles by means of electromagnetic RF radiation. The foam particles are made of polyurethane (PU), polylactate (PLA), polyethylene block amide (PEBA) or polyethylene terephthalate (PET).

Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitor of formula III or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to the use of tyrosine kinase inhibitors, selected from nintedanib and pharmaceutically acceptable salts thereof, for the treatment of muscular dystrophy.

Abstract: Disclosed are substituted quinolines of formula 1 wherein R1 and R2 are defined herein, the processing of making and using the same.

Abstract: Disclosed are substituted quinolines of formula 1 wherein R1 and R2 are defined herein, the processing of making and using the same.

Abstract: Disclosed are substituted quinolines of formula 1 wherein R1 and R2 are defined herein, the processing of making and using the same.

Abstract: Disclosed are substituted quinolines of formula 1 wherein R1 and R2 are defined herein, the processing of making and using the same.

Abstract: The invention relates to the use of at least one caspase inhibitor, in particular a caspase-3 inhibitor, for preparing a pharmaceutical composition for the prophylaxis or therapy of a viral infection, in particular an infection with an RNA negative-strand virus, preferably an influenza infection, and to a test system for identifying suitable active substances.

Abstract: A self-adhesive flashing for integrating a flanged fenestration unit installed in a rough opening in a wall with a weather resistive barrier is disclosed where the flashing includes an elongated substrate having a pressure-sensitive adhesive layer adhered to one side of the substrate such that a first portion of the adhesive layer covers a portion of the substrate adjacent a lateral edge of the substrate and a second portion of the adhesive layer extends beyond the lateral edge.

Abstract: The invention relates to the use of at least one caspase inhibitor, in particular a caspase-3 inhibitor, for preparing a pharmaceutical composition for the prophylaxis and/or therapy of a viral infection, in particular an infection with an RNA negative-strand virus, preferably an influenza infection, and to a test system for identifying suitable active substances.